Edition:
United Kingdom

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

8.48USD
17 Aug 2018
Change (% chg)

$-0.27 (-3.09%)
Prev Close
$8.75
Open
$8.79
Day's High
$8.79
Day's Low
$8.45
Volume
80,816
Avg. Vol
96,772
52-wk High
$14.62
52-wk Low
$4.89

Latest Key Developments (Source: Significant Developments)

Adaptimmune Announces Favorable Review Of Safety From One Billion Cell Dose Cohort In Mage-A10 Spear T-Cell Study
Wednesday, 18 Jul 2018 

July 18 (Reuters) - Adaptimmune Therapeutics PLC ::ADAPTIMMUNE ANNOUNCES FAVORABLE REVIEW OF SAFETY FROM ONE BILLION CELL DOSE COHORT IN MAGE-A10 SPEAR T-CELL STUDY AND INITIATION OF THIRD DOSING COHORTS.ADAPTIMMUNE THERAPEUTICS PLC - SAFETY REVIEW COMMITTEE ENDORSED DOSE ESCALATION TO THIRD DOSE COHORTS IN BOTH MAGE-A10 PILOT STUDIES.ADAPTIMMUNE THERAPEUTICS PLC - NO EVIDENCE OF TOXICITY RELATED TO OFF-TARGET BINDING OR ALLOREACTIVITY HAS BEEN REPORTED.  Full Article

Adaptimmune Announces First Patient To Receive One Billion Target Cell Dose After Positive Safety Data
Monday, 4 Jun 2018 

June 4 (Reuters) - Adaptimmune Therapeutics PLC ::ADAPTIMMUNE ANNOUNCES FIRST PATIENT TO RECEIVE ONE BILLION TARGET CELL DOSE AFTER POSITIVE SAFETY DATA FROM PILOT STUDY WITH MAGE-A4 SPEAR T-CELLS.ADAPTIMMUNE THERAPEUTICS - NO EVIDENCE OF OFF-TARGET TOXICITY AT 100 MILLION CELLS FOR SECOND WHOLLY OWNED ASSET.ADAPTIMMUNE THERAPEUTICS PLC - SYNOVIAL SARCOMA AND MRCLS ADDED TO SEVEN SOLID TUMORS ALREADY IN MAGE-A4 BASKET STUDY.ADAPTIMMUNE THERAPEUTICS PLC - WILL START TREATING PATIENTS WITH TARGET DOSE OF ONE BILLION TRANSDUCED MAGE-A4 SPEAR T-CELLS IN ONGOING BASKET STUDY.  Full Article

Adaptimmune Therapeutics Says On Jan 5, Co Entered Into Agreement With Cell, Gene Therapy Catapult For Vector Production In UK
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Adaptimmune Therapeutics Plc ::ADAPTIMMUNE THERAPEUTICS SAYS ON JAN 5, CO ENTERED INTO AGREEMENT WITH CELL AND GENE THERAPY CATAPULT FOR VECTOR PRODUCTION IN UK - SEC FILING.ADAPTIMMUNE THERAPEUTICS - AGREEMENT IS FOR TERM OF 5 YEARS WITH EARLIER TERMINATION AVAILABLE TO BOTH PARTIES ON PROVISION OF 12 MONTHS' NOTICE.ADAPTIMMUNE THERAPEUTICS PLC - AGREEMENT WILL ENABLE CO TO HAVE ITS OWN DEDICATED VECTOR MANUFACTURING SPACE IN UK.ADAPTIMMUNE - AGREEMENT TO ENSURE VECTOR SUPPLY PRODUCTION BEYOND 2020 FOR ONGOING STUDIES WITH 3 SPEAR T-CELL THERAPIES, MAGE-A4, MAGE-A10 AND AFP.  Full Article

Adaptimmune Announces Positive Safety Data From Pilot Studies With MAGE-A10 SPEAR T-Cells
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Adaptimmune Therapeutics Plc :::ADAPTIMMUNE ANNOUNCES POSITIVE SAFETY DATA FROM PILOT STUDIES WITH MAGE-A10 SPEAR T-CELLS AND FIRST PATIENT TO RECEIVE 1 BILLION TARGET CELL DOSE.ADAPTIMMUNE THERAPEUTICS PLC - NO EVIDENCE OF TOXICITY RELATED TO OFF-TARGET BINDING OR ALLOREACTIVITY HAS BEEN OBSERVED.ADAPTIMMUNE - IN NSCLC STUDY, THERE HAS BEEN ONE SERIOUS ADVERSE EVENT OF CYTOKINE RELEASE SYNDROME, A GRADE 4 EVENT THAT RESOLVED WITH TREATMENT.ADAPTIMMUNE THERAPEUTICS PLC - ADVERSE EVENT OF CYTOKINE RELEASE SYNDROME IN NSCLC STUDY LED TO COHORT 1 EXPANSION FROM 3 TO 6 PATIENTS.  Full Article

Adaptimmune Therapeutics Q3 loss per share $0.00
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Adaptimmune Therapeutics Plc :Adaptimmune reports third quarter 2017 financial results and business updates.Q3 revenue $27.2 million versus $2.4 million.Q3 revenue view $6.3 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.00.Adaptimmune- existing cash, cash equivalents, securities, income from GSK on transition of NY-ESO program to fund operating plan through to early 2020​.  Full Article

BRIEF-Adaptimmune Reports Q1 Loss Per Share $0.04

* ADAPTIMMUNE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE